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The centralized and public availability of molecular sequence and clinical trial data presents an opportu-
nity to identify potentially valuable linkages across the bench-to-bedside ‘‘T1” translational barrier. In
this study, we sought to leverage keyword metadata (Medical Subject Heading [MeSH] descriptors) to
infer relationships between molecular sequences and clinical trials, as indexed by GenBank and Clinical-
Trials.gov. The results of this feasibility study found that approximately 30% of sequences in GenBank
could be linked to trials and over 90% of trials in ClinicalTrials.gov could be linked to sequences through
MeSH descriptors. In a cursory evaluation, we were able to consistently identify meaningful linkages
between molecular sequences and clinical trials. Based on our ﬁndings, there may be promise in subse-
quent studies aiming to identify linkages across the T1 translational barrier using existing large
repositories.
 2009 Elsevier Inc. All rights reserved.1. Introduction
Core to the success of translational bioinformatics endeavors
will be the ability to link relevant information across the bench-
to-bedside translational barrier (‘‘T1”). Insights across this barrier
inherently involve the linking of bench-based research data with
relevant clinical information. To date, many studies that aim to
bridge across the T1 translational barrier have focused on the study
of de novo data. To this end, there have been limited explorations
into the development of a semantic infrastructure for linking clin-
ical trial data to relevant molecular data.
Clinical hypotheses can often involve the direct manipulation of
genetic material (such as in animal models) or the development of
targeted interventions that interact with a particular molecule. As
clinical hypotheses are tested, putative successful interventions are
incorporated into clinical trials. As publications describe the back-
ground and results of a clinical trial, they are often cataloged in
centralized resources. For example, this may be especially impor-
tant when considering the identiﬁcation of molecules or molecular
properties that may be relevant in the context of a particular com-
bination of disease phenotypes. As interventions are assessed for
their clinical efﬁcacy and effectiveness, it may be imperative to
identify linkages to underlying molecular mechanisms. Drawing
correlations between bench and bedside research collectively com-ll rights reserved.
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, VT 05405, USA.prise the ‘‘holy grail” for translational bioinformatics, yet this can
be often hindered by limited availability of data sets that can be
cross-linked. Previous work has explored the ability and challenges
to navigating information resources (e.g., MedlinePlus, ClinicalTri-
als.gov, OMIM, and PubMed/MEDLINE) from phenotype to geno-
type to answer speciﬁc questions about genes and gene products
related to speciﬁc diseases (e.g., ‘‘What genes cause the disease?”
and ‘‘Are there gene therapies or clinical trials for this disease?”)
[1]. Major challenges to linking or integration of these resources in-
cluded data complexity, dynamic data, diverse foci and number of
resources, and lack of standardized data and knowledge represen-
tation. Numerous efforts have emerged to address these data and
knowledge integration issues in different contexts (e.g., transla-
tional research [2] and biology [3]).
Both the molecular and clinical trial communities have em-
braced the use of centralized repositories [4]. Within the molecular
biology community, almost all reference molecular sequence data
are publicly available via GenBank (presently containing over 100
million records) [5]; ClinicalTrials.gov is a publicly accessible re-
source that catalogs clinical trials (presently containing over 75
thousand records) [6,7]. Both resources are maintained by the Na-
tional Library of Medicine (NLM) (the former by the National Cen-
ter for Biotechnology Information [NCBI] and the latter by the
Lister Hill National Center for Biomedical Communications in col-
laboration with the Food and Drug Administration) and readily
downloadable.
Many of the NLM/NCBI resources are cross-linked through the
Entrez interface and are collectively searchable from a single inter-
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For example, it is possible to identify both articles in PubMed/
MEDLINE and molecular sequences in GenBank that are associated
with a given topic. The strong relationship between GenBank and
publications that are largely indexed in MEDLINE [10] can lead to
inferred annotations of molecular sequence data. Recent work
has shown how these Entrez-based relationships can lead to ap-
proaches to link molecular information to relevant literature
(e.g., identify keyword descriptors that are associated with publi-
cations that are afﬁliated with a group of related molecular se-
quences) [11]. Within ClinicalTrials.gov, keyword descriptors are
explicitly applied to entries. Additional keyword descriptors can
also be inferred, as in the case with GenBank entries, through asso-
ciated publications.
Keyword descriptors that are part of controlled vocabulary or
ontological structures can be leveraged for linking putatively re-
lated data elements. Preliminary studies demonstrate the possibil-
ity of leveraging existing semantic infrastructures to link genotypic
information (e.g., as captured in molecular databases) to pheno-
typic (e.g., as captured in stores of clinical data). For example, pre-
vious work has demonstrated how one might make use of the
Uniﬁed Medical Language System (UMLS) to link clinical concepts
primarily represented in the Systematized Nomenclature of Medi-
cine (SNOMED) to genomic concepts represented in the Gene
Ontology (GO) [12,13]. Additional work has explored how the con-
trolled vocabulary primarily associated with MEDLINE, the Medical
Subject Headings (MeSH) [14], can be used to link disparate re-
sources (e.g., OMIM, UMLS Metathesaurus, and GenBank [15]) or
identify possibly linked concepts [16]. In contrast to speciﬁc do-
main terminologies, such as SNOMED or GO, MeSH is designed pri-
marily as an indexing terminology to capture the breadth of
biomedical science that is required to meet information needs
associated with the PubMed/MEDLINE interface. Thus, while lack-
ing potential deeper levels of domain knowledge (as leveraged by
other semantic mediated linkage systems [17,18]), MeSH provides
a broad list of concepts that may provide some traction for linking
relevant objects to each other across the translational spectrum.
For example, through a series of MeSH based queries to PubMed/
MEDLINE, it is possible to identify relevant citations that are re-
lated to each other across the entire spectrum of translational
bioinformatics.
Building on the premise that MeSH-based annotations can be
used to link related concepts, this study explores the feasibility
of linking molecular sequence and clinical trial data leveraging
MeSH descriptors either directly associated with clinical trials or
inferred from published literature (i.e., PubMed/MEDLINE).2. Materials and methods
For this feasibility study, the overall approach involved three
major phases: (1) collecting PubMed Identiﬁers (PMIDs) and MeSH
descriptors from GenBank, ClinicalTrials.gov, and PubMED/MED-
LINE; (2) characterizing and ﬁltering by MeSH descriptors; and,
(3) identifying linkages between molecular sequences and clinical
trials based on PMIDs and MeSH.2.1. Data collection
Literature references and MeSH descriptors associated with se-
quences in GenBank and studies in ClinicalTrials.gov were col-
lected. Fig. 1 depicts the approach for extracting this information
from GenBank, ClinicalTrials.gov, and PubMed/MEDLINE. Each step
in the overall process is further described in the following sections.2.1.1. Molecular sequences from GenBank
Molecular sequence data represent a fundamental component
in many bench research endeavors. GenBank is a centralized repos-
itory for cataloging molecular sequence data [5]. Through partner-
ships via the International Nucleotide Sequence Database
Collaboration (INSDC), GenBank data are globally synchronized
with European (EMBL) and Asian (DDBJ) repositories, thus repre-
senting a complete collection of nearly all publicly available molec-
ular sequence data. Associated with each sequence entry in
GenBank is a detailed set of metadata elements, organized into
general bibliographic metadata and a ‘‘Feature Table” as deﬁned
by the INSDC. Included among the over 70 metadata elements
are ﬁelds like ‘‘ACCESSION” representing the unique identiﬁer for
the sequence and ‘‘REFERENCE” for literature relevant to the se-
quence that includes ‘‘AUTHOR,” ‘‘TITLE,” ‘‘JOURNAL,” and ‘‘PUB-
MED” conveying the citation and PMID. In a recent study, a
signiﬁcant portion (30%) of GenBank records was found to be
associated with PubMed/MEDLINE records through the PMIDs
[11]. Preliminary analyses have demonstrated the ability to lever-
age PMIDs to identify MeSH descriptors that are associated with a
given GenBank record.
The entirety of GenBank is freely downloadable from NCBI [19].
A series of scripts was developed to extract and load GenBank
metadata into a MySQL database thus enabling rapid query of Gen-
Bank records (e.g., ‘‘Which sequences have reference informa-
tion?”). For sequences with references, E-Utilities was used to
obtain the associated MeSH descriptors using the PMIDs
(Fig. 1A). This set of references and MeSH descriptors derived from
information in GenBank was supplemented by information from
PubMed/MEDLINE. Speciﬁcally, E-Utilities was used to query Pub-
Med/MEDLINE directly to identify records containing information
about molecular sequence data through the ‘‘Secondary Source
ID” (SI) ﬁeld (e.g., SI – GENBANK/AF306859) [20]; MeSH descrip-
tors were then obtained for the corresponding PMIDs (Fig. 1B).
The combined sets of PMIDs and MeSH descriptors will henceforth
be referred to as GB/PMID and GB/P-MeSH, respectively.
2.1.2. Clinical trials from ClinicalTrials.gov
Clinical trials represent a primary means for evaluating the
safety and efﬁcacy of new therapies and other interventions that
have the potential for improving clinical practice. ClincialTrials.gov
was developed in response to legislation mandating a comprehen-
sive, publically accessible registry of federally and privately funded
clinical trials [6,7]. This Web-based registry maintains a common
set of data elements for each trial including 40 major required
and optional elements for descriptive information, recruitment
information, location and contact information, administrative data,
and optional supplementary information. Information about stud-
ies registered in ClinicalTrials.gov is viewable from the public Web
site and can be downloaded as plain text or XML ﬁles from this site
[21]. To facilitate registration of trial information from organiza-
tions, a Web-based data entry and management system called
the Protocol Registration System was created [22,23].
Required elements associated with each registered study in-
clude study identiﬁer, brief title, recruitment status, sponsor or
funding source, eligibility criteria, study design, condition(s), and
intervention(s). Optional elements may include investigators, ref-
erences for background citations, references for completed studies,
and keywords. The use of MeSH for conditions, interventions, and
keywords is requested if possible; however, part of the data prep-
aration phase of the registration process involves mapping to
MeSH descriptors as needed and high-level MeSH categories [6,7].
Based on a preliminary review of content within the XML ﬁles
and Web pages for ClinicalTrials.gov, we observed that a combina-
tion of sources and methods would be needed to extract a more
complete set of literature references and MeSH descriptors associ-
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Fig. 1. Collecting literature references and MeSH descriptors for molecular sequences and clinical trials. References (citation and/or PubMed Identiﬁer [PMID]) associated
with sequences (indicated by a unique Accession Identiﬁer [ACC ID]) in GenBank were obtained (A). Records (indicated by a unique PMID) in PubMed/MEDLINE that include
Accession IDs for sequences in GenBank were also identiﬁed (B). The combined set of PMIDs from GenBank and PubMed/MEDLINE is ‘‘GB/PMID” and the set of MeSH
descriptors for these PMIDs is ‘‘GB/P-MeSH”. Background and results references (citation and/or PubMed Identiﬁer [PMID]) were obtained from XML ﬁles for studies
(indicated by a National Clinical Trials Identiﬁer [NCT ID]) in ClinicalTrials.gov (1). Records (indicated by a unique PMID) in PubMed/MEDLINE that include NCT IDs for studies
in ClinicalTrials.gov were also identiﬁed; these include additional references listed on the CLinicalTrials.gov public Web site (2). The combined set of PMIDs from GenBank and
PubMed/MEDLINE is ‘‘CT/PMID” and the set of MeSH descriptors for these PMIDs is ‘‘CT/P-MeSH”. The set of MeSH descriptors obtained directly for studies from the
ClinicalTrials.gov Web pages is ‘‘CT/C-MeSH” (3). The combination of MeSH descriptors (explicit and obtained through PMIDs) for ClinicalTrials.gov is ‘‘CT/CP-MeSH”.
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they are represented in the ClinicalTrials.gov XML ﬁles, what head-
ers they appear under in the ClinicalTrials.gov Web pages, and
sources used to collect this information. The speciﬁc sources are:
(1) XML ﬁles from ClinicalTrials.gov for the full studies (Fig. 1 –
1), (2) HTML pages from the ClinicalTrials.gov public Web site
(Fig. 1 – 2), and (3) PubMed/MEDLINE (Fig. 1 – 3).
Using the ‘‘Download Options” feature in ClinicalTrials.gov, the
XML ﬁles for all full studies were downloaded. Each XML ﬁle was
parsed according to the Document Type Deﬁnition (DTD) [24] to
extract basic metadata (e.g., National Clinical Trials Identiﬁer
[NCT ID] and title) and metadata associated with references. TheseTable 1
Elements and sources for literature references associated with studies in
ClinicalTrials.gov.
Element XML element Public Web
site headers
Source
Background
Reference
reference Publications ClinicalTrials.gov XML
Results
Reference
results_reference Publications ClinicalTrials.gov XML
MeSH
Descriptor
N/A ‘‘Additional
relevant MeSH
terms”
ClinicalTrials.gov Web
page
Additional
Reference
N/A ‘‘Additional
publications
automatically
indexed to this
study by National
Clinical Trials
Identiﬁer (NCT
ID)”
PubMed/MEDLINE
(E-Utilities)references either represent literature that provide background for
the study (‘‘Background References”) or report on results from
the study (‘‘Results References”). For either type of reference, the
PMID, full citation, or both may be provided. In cases where a PMID
was available, E-Utilities was used to retrieve associated MeSH
descriptors. Similar to our GenBank analysis, E-Utilities was used
to query PubMed/MEDLINE to identify any additional references
for clinical trials; these include references displayed on the Clini-
calTrials.gov Web pages that are not in the corresponding XML ﬁle
and are difﬁcult to extract from the Web pages or any others that
may be indicated by the ‘‘SI” ﬁeld in PubMed/MEDLINE (e.g., SI –
ClinicalTrials.gov/NCT00000419). MeSH descriptors associated
with these records were similarly obtained for the corresponding
PMIDs. The combined sets of PMIDs and MeSH descriptors will
henceforth be referred to as CT/PMID and CT/P-MeSH, respectively.
Finally, in examining the content displayed on the ClinicalTri-
als.gov public Web site for studies, we found that some informa-
tion was not included in the XML ﬁles such as keywords, topic
categories, and MeSH descriptors. To add these MeSH descriptors
into the data set, we processed each Web page associated with a
study to extract this information. This set of MeSH descriptors is
referred to as CT/C-MeSH to represent MeSH descriptors obtained
directly from ClinicalTrials.gov rather than through PubMed/MED-
LINE; the set resulting from the combination of this set with CT/P-
MeSH will be called CT/CP-MeSH.2.2. Characterizing and ﬁltering by MeSH
An analysis of the four sets of MeSH descriptors collected for se-
quences in GenBank and studies in ClinicalTrials.gov (GB/P-MeSH,
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determine the distribution of descriptors across the 16 top-level
MeSH 2009 categories. This analysis revealed that the hierarchies
with the highest frequency based on the combined set of MeSH
descriptors for clinical trials (CT/CP-MeSH) were ‘‘Diseases” (Cate-
gory C) and ‘‘Chemicals and Drugs” (Category D). These two catego-
ries were used to ﬁlter each of the MeSH descriptor sets in order to
use more focused and condensed sets to test the feasibility of link-
ing molecular sequences and clinical trials through MeSH. In addi-
tion, due to the large size of GenBank, GB/P-MeSH was further
ﬁltered to include only the MeSH descriptors also occurring in
the sets for clinical trials.2.3. Linking molecular sequences and clinical trials
Based on the PMID and MeSH descriptor sets, two major types
of linkages can be obtained: (1) links between sequences and trials
through PMID and (2) links between sequences and trials through
MeSH. The former can enable the ability the answer questions like:
‘‘For a given sequence, what clinical trials may be of interest, what
literature is associated with both the sequence and trials, and what
other literature associated with the trials may be of interest?” or
‘‘For a given trial, what sequences may be of interest, what litera-
ture is associated with both the sequences and trial, and what
other literature associated with the sequences may be of inter-
est?”. The latter may enhance the answers provided by the PMIDs
alone by identifying additional linkages through common MeSH
descriptors.
Using the GB/PMID and CT/PMID sets, links between sequences
and trials were identiﬁed based on common PMIDs. Three sets of
linkages were identiﬁed between the MeSH descriptor set for se-
quences (GB/P-MeSH) and MeSH descriptor sets for trials (CT/C-
MeSH, CT/P-MeSH, and CT/CP-MeSH). Due to the potentially large
number of and possibly irrelevant links, a score was calculated to
measure the relevancy of each link based on the number of com-
mon MeSH descriptors between a given sequence and trial. In
the case of links from trials to sequences, the general algorithm
was as follows: (1) get all associated MeSH descriptors for the trial,
(2) identify sequences with at least two MeSH descriptors in com-
mon with the trial, and (3) determine the strength of the link by
calculating the proportion of MeSH descriptors in common. For
example, if Trial A = {MeSH1, MeSH2, MeSH3, MeSH4, MeSH5,
MeSH6}, Sequence B = {MeSH1, MeSH4}, and Sequence
C = {MeSH1, MeSH2, MeSH3, MeSH5}, then Score(Trial A, Sequence
B) = 0.33 and Score(Trial A, Sequence C) = 0.67.3. Results
3.1. Molecular sequences and clinical trials
GenBank (Release 172) was downloaded, processed, and loaded
into a MySQL database for further querying in July 2009. Out of the
over one hundred million sequences, 30.13% are associated with
references from PubMed/MEDLINE, speciﬁcally 43,540,315 total
PMIDs and 298,646 unique PMIDs. An E-Utilities query to Pub-
Med/MEDLINE performed on July 9, 2009 identiﬁed 99,230 addi-
tional unique articles with 1,493,439 associated Accession IDs
representing sequences in GenBank. The combination of these sets
included 35,128,847 (30.36%) sequences with 313,612 unique
PMIDs (GB/PMID set).
Full studies for all clinical trials were downloaded from Clinical-
Trials.gov as separate XML ﬁles on July 6, 2009. This set included
74,853 trials from 167 countries. Each XML ﬁle was processed to
extract basic information and references associated with the study.
Out of the total number of trials, 14,320 (19.13%) included 70,307background and/or results references where 91.98% of these refer-
ences are associated with 64,669 total PMIDs and 56,167 unique
PMIDs. An E-Utilities query to PubMed/MEDLINE performed on
July 8, 2009 identiﬁed 3790 articles with 3397 associated NCT
IDs representing studies in ClinicalTrials.gov. Combining these
two sets resulted in 15,674 unique trials (20.94%) with 59,234 un-
ique PMIDs (CT/PMID set). Table 2 depicts the breakdown of refer-
ences by type (background or results) and source
(ClinicalTrials.gov or PubMed/MEDLINE).
Using E-Utilities to query PubMed/MEDLINE, MeSH descriptors
were obtained for each PMID in GB/PMID and CT/PMID to produce
GB/P-MeSH and CT/P-MeSH, respectively. In addition, MeSH
descriptors for each trial were extracted from the corresponding
ClinicalTrials.gov Web pages to generate CT/C-MeSH. The CT/P-
MeSH and CT/C-MeSH sets were then combined to create CT/CP-
MeSH. Table 3 summarizes the number of unique sequences or tri-
als, total number of MeSH descriptors, and total number of unique
MeSH descriptors associated with each of these sets.
3.2. MeSH hierarchy characterization
The top-level hierarchy for each MeSH descriptor in GB/P-
MeSH, CT/P-MeSH, CT/C-MeSH, and CT/CP-MeSH was identiﬁed.
Table 4 and Fig. 2 depict the distribution of descriptors across
the sixteen hierarchies. The top three hierarchies were ‘‘Phenom-
ena and Processes” (37.23%), ‘‘Organisms” (15.43%), and ‘‘Chemi-
cals and Drugs” (12.63%) for GB/P-MeSH; ‘‘Diseases” (53.80%),
‘‘Chemicals and Drugs” (41.15%), and ‘‘Psychiatry and Psychology”
(3.40%) for CT/C-MeSH; ‘‘Analytical, Diagnostic and Therapeutic
Techniques and Equipment” (20.02%), ‘‘Technology, Industry, Agri-
culture” (20.2%), and ‘‘Chemical and Drugs” (13.77%) for CT/P-
MeSH; and, ‘‘Diseases” (31.48%), ‘‘Chemicals and Drugs” (26.74%),
‘‘Analytical, Diagnostic and Therapeutic Techniques and Equip-
ment” (10.75%), and ‘‘Technology, Industry, Agriculture” (10.75%)
for CT/CP-MeSH. The sets were subsequently ﬁltered by ‘‘Diseases”
and ‘‘Chemicals and Drugs” (the top two hierarchies based on CT/C-
MeSH and CT/CP-MeSH) and GB/P-MeSH was further ﬁltered to in-
clude descriptors only occurring in the clinical trials sets.
3.3. Molecular sequence and clinical trial linkages
3.3.1. Linking molecular sequences and clinical trials through PMID
The PMIDs from GB/PMID and CT/PMID were used to identify
links between molecular sequences and clinical trials. A total num-
ber of 78,259 links were identiﬁed involving 64,181 sequences and
426 trials. For a given sequence, the minimum number of links to
trials was 1 and the maximum was 6; for a given trial, the number
of links to sequences ranged from a minimum of 1 to a maximum
of 41,152. Fig. 3 depicts the sequences and literature references
linked to the trial ‘‘Family Studies of Inherited Heart Disease”
(NCT ID = NCT00001225) and Fig. 4 lists the trials and literature
references linked to the sequence ‘‘Homo sapiens Huntington’s Dis-
ease (HD) mRNA, complete cds.” (Accession ID = HUMHDA).
3.3.2. Linking molecular sequences and clinical trials through MeSH
Through MeSH descriptors in the ‘‘Diseases” and ‘‘Chemicals
and Drugs” hierarchies, three sets of linkages between sequences
and trials were identiﬁed (Table 5). Over 39 billion links were gen-
erated from GB/P-MeSH and CT/C-MeSH covering 90.41% of the tri-
als, over 800 million were identiﬁed for CT/P-MeSH involving
18.72% of the total trials, and the combined set of CT/CP-MeSH re-
sulted in almost 40 billion links for 91.6% of the trials. The esti-
mated upper bound for the number of sequences involved in
each of these sets was about 35 million (30.00%).
For each link, the relevancy score was calculated based on the
number of common MeSH descriptors to enable the ranking of se-
Table 2
Total number of literature references, unique PMIDs or citations, and unique trials.
ClinicalTrials.gov All references References with PMID References with no PMID
Total # Unique citations # Unique trials Total # Unique PMID # Unique trials Total # Unique citations # Unique trials
Background References 60,840 53,135 10,937 57,132 49,513 10,539 3708 3516 1474
Results References 9467 9235 4179 7537 7322 3581 1930 1913 1173
All References 70,307 61,695 14,320 64,669 56,167 13,465 5638 5419 2513
PubMed/MEDLINE 3790 3790 3397 3790 3790 3397 N/A N/A N/A
Total (CT/PMID) 59,234 15,674
Table 3
Total and unique number of MeSH descriptors associated with sequences and trials.
# Sequences or trials # Total MeSH # Unique MeSH (%)a
GB/P-MeSH 34,717,804 761,211,303 18,801 (74.65)
CT/C-MeSH 69,196 954,985 5105 (20.27)
CT/P-MeSH 15,366 948,756 14,611 (58.01)
CT/CP-MeSH 70,213 1,903,741 16,063 (63.78)
a Percent of descriptors in MeSH 2009 (n = 25,186).
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quences relative to trials based on the relevancy scores. CT/C-MeSH
by itself was able to identify relevant sequences across all clinical
trials. By contrast, CT/P-MeSH by itself does not offer as many sig-
niﬁcant sequences that are related to clinical trials. The combined
set of MeSH descriptors (CT/CP-MeSH) was not dramatically af-
fected by CT/P-MeSH; however, there were a number of instances
where even if no CT/C-MeSH descriptors were available that CT/P-
MeSH was able to facilitate the identiﬁcation of relevant molecular
sequences. As an example, Fig. 6 presents MeSH descriptors and
the MeSH-based links to sequences for the same trial in Fig. 3.4. Discussion
The development of approaches for identifying potential link-
ages across disparate data sources is essential towards the genera-
tion of putative testable hypotheses. Within the scope of
translational bioinformatics, such hypotheses include those that
aim to identify potentially related molecular sequences and clinical
trials, thus transcending the ‘‘T1” bench-to-bedside translational
barrier. In the present study, we were able to demonstrate the abil-
ity to link molecular sequences from GenBank to relevant clinicalTable 4
Number of MeSH descriptors associated with sequences and trials in each hierarchy.
Top-level hierarchy Sequences
GB/P-MeSH
Total
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] 91,840,52
Anatomy [A] 28,317,59
Anthropology, Education, Sociology and Social Phenomena [I] 2,110,32
Chemicals and Drugs [D] 109,383,26
Disciplines and Occupations [H] 27,335,27
Diseases [C] 11,253,22
Geographicals [Z] 9,664,56
Health Care [N] 30,093,42
Humanities [K] 71,91
Information Science [L] 82,607,61
Named Groups [M] 5,052,40
Organisms [B] 133,595,92
Phenomena and Processes [G] 322,307,09
Psychiatry and Psychology [F] 1,363,48
Publication Characteristics [V] 10,744,79
Technology, Industry, Agriculture [J] 91,840,52trials in ClinicalTrials.gov and vice versa. Using MeSH descriptors
associated with GenBank records (through PubMed/MEDLINE)
and MeSH descriptors associated with ClinicalTrials.gov records
(either directly, through PubMed/MEDLINE, or in combination),
linkable molecular sequences and clinical trials can be identiﬁed.
The linkage between human-centric (e.g., ClinicalTrials.gov) and
organism-agnostic (e.g., GenBank) resources presents an opportu-
nity to identify putative model organisms for a given disease. We
are currently working to develop an approach that leverages the
results of the present study to discover potentially interesting
organisms that may be associated with a clinical condition. In this
study, the entirety of GenBank was considered to determine the
feasibility of developing potentially meaningful linkages from Clin-
icalTrials.gov; however, the nature of sequences in GenBank is such
that there are often numerous similar or even identical sequences.
As a possible way to address this, we are planning to leverage cu-
rated molecular sequence resources such as RefSeq [25] or Uni-
Gene [26]. Additionally, we anticipate that the use of RefSeq or
UniGene will help lead to a more statistically relevant understand-
ing of the linkages between clinical trials and available molecular
sequence data (by ﬁltering out redundant sequences).
In this study, literature references associated with either Gen-
Bank or ClinicalTrials.gov were used as a surrogate for annotations.
There is a keyword ﬁeld in GenBank; however, it is not associated
with a speciﬁc controlled vocabulary like MeSH. References in Clin-
icalTrials.gov are categorized as either ‘‘background” or ‘‘result”
citations. In the present study, we treated these two references
equivocally; however, it may be interesting to study the effect of
using either of these category types exclusively compared with
their combination. During our processing of ClinicalTrials.gov data,
we observed that there were references that did not have a PMID
(thus preventing an easy linkage to PubMed/MEDLINE). Future
work could therefore involve reviewing these to determine whyClinical trials
CT/C-MeSH CT/P-MeSH CT/CP-MeSH
% Total % Total % Total %
3 10.61 4325 0.45 211,541 20.02 215,866 10.75
9 3.27 237 0.02 39,980 3.78 40,217 2.00
4 0.24 55 0.01 14,673 1.39 14,728 0.73
5 12.63 391,588 41.15 145,454 13.77 537,042 26.74
4 3.16 0 0.00 5758 0.55 5758 0.29
8 1.30 511,887 53.80 120,240 11.38 632,127 31.48
0 1.12 0 0.00 12,637 1.20 12,637 0.63
8 3.48 191 0.02 138,840 13.14 139,031 6.92
5 0.01 0 0.00 2359 0.22 2359 0.12
9 9.54 0 0.00 20,317 1.92 20,317 1.01
0 0.58 0 0.00 121,045 11.46 121,045 6.03
8 15.43 0 0.00 86,481 8.19 86,481 4.31
0 37.23 7622 0.80 94,470 8.94 102,092 5.08
8 0.16 32,391 3.40 36,922 3.49 69,313 3.45
4 1.24 3248 0.34 5768 0.55 9016 0.45
3 10.61 4325 0.45 211,541 20.02 215,866 10.75
Fig. 2. Distribution of MeSH descriptors across the top-level hierarchies for sequences and trials.
Fig. 3. PMID-based links for trial in ClinicalTrials.gov, NCT00001225 (Family Studies of Inherited Heart Disease). This study is associated with three articles (PMID: 1975517,
2022018, and 2144212). Links to four sequences were identiﬁed (A) where two articles were found to be common to the trial and sequences (B) and nine other articles
associated with the sequences may be of interest (C).
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MEDLINE).
Because our approach to supplement the MeSH descriptors for
both molecular sequences and clinical trials depended on PMIDs,
a complete list of associated PMIDs was required for each sequence
or trial. However, an interesting ﬁnding was that it was not possi-
ble to reliably get a complete list directly from either GenBank or
ClinicalTrials.gov. For GenBank, previous work has characterized
the types of discordance between which PMIDs are reported from
GenBank compared with those that are in PubMed/MEDLINE [11].
Performing a similar type of analysis on ClinicalTrials.gov data re-
veals a similar trend (Fig. 7). This further underscores the chal-
lenges in curating, maintaining, and synchronizing large
repositories like GenBank, ClinicalTrials.gov, and PubMed/MED-
LINE. Nonetheless, the infrastructure is in place for explicitly link-
ing between key resources (e.g., PubMed/MEDLINE to GenBank or
PubMed/MEDLINE to ClinicalTrials.gov). Interestingly, a PubMed/MEDLINE search for records that are associated with both GenBank
and ClinicalTrials.gov records (as recorded in the ‘‘Secondary Iden-
tiﬁer” [SI] ﬁeld) only retrieves two articles (PMID 16525138 and
16525137; query performed on August 31, 2009).
The present study focused on keyword metadata in the form of
MeSH descriptors. Both GenBank and ClinicalTrials.gov have asso-
ciated metadata ﬁelds that contain additional potentially valuable
keyword terms that might be used to develop more reliable and
complete linkages. For example, examination of the GenBank key-
word ﬁeld reveals that there are over 2 million terms (compared to
the over 25,000 MeSH descriptors available). A possible future area
of work may thus be to map these keywords to a hierarchy such as
MeSH to get a more direct annotation of molecular sequence data
as a comparison to those inferred by PubMed/MEDLINE. With re-
spect to ClinicalTrials.gov, other potential keywords (many of
which might be directly derived from MeSH) include keywords
provided by the sponsors or organizations (e.g., ‘‘Keywords pro-
Fig. 4. PMID-based links for sequence in GenBank, HUMHDA (Homo sapiens Huntington’s Disease (HD) mRNA, complete cds. ). This sequence is associated with one article
(PMID: 8458085). Links to three trials were identiﬁed (A) where one article was found to be common to the sequence and trials (B) and 71 other articles associated with the
trials may be of interest (C).
Table 5
Number of PMID- and MeSH-based links between sequences and trials.
GenBank ClinicalTrials.gov # Sequences # Trials # Links
GB/PMID CT/PMID 64,181 426 78,259
GB/P-MeSH CT/C-MeSH 34,717,804a 67,672 39,109,150,340
GB/P-MeSH CT/P-MeSH 34,717,804a 14,010 823,561,641
GB/P-MeSH CT/CP-MeSH 34,717,804a 68,567 39,791,577,560
a Estimated upper bound.
448 E.S. Chen, I.N. Sarkar / Journal of Biomedical Informatics 43 (2010) 442–450vided by National Institutes of Health Clinical Center (CC)”), topic
categories, conditions, and interventions. We have begun an anal-Fig. 5. MeSH-based relevancy of molecular sequences linked to clinical trials. The numbe
according to their relevancy (X-axis, on a scale of 0 [not relevant] – 100 [highly relevanysis of these terms and have started identifying mechanisms to
map them to MeSH descriptors (e.g., using natural language pro-
cessing techniques). Finally, in considering PubMed/MEDLINE, we
only focused on the use of MeSH descriptors. Next steps include
making better use of MeSH qualiﬁers and substances to help iden-
tify additional linkages as well as help quantify the importance of
linkages that are identiﬁed using solely MeSH.
One part of this study involved characterizing MeSH descriptors
by identifying their corresponding hierarchies or categories in
MeSH 2009. This characterization provided insights on the distri-
bution of descriptors across MeSH hierarchies for molecular se-
quences compared with clinical trials and assisted in identifyingr of molecular sequences that were linkable across all clinical trials (Y-axis) is shown
t]).
Fig. 6. MeSH-based links for trial in ClinicalTrials.gov, NCT00001225 (Family Studies of Inherited Heart Disease). Fifteen MeSH descriptors are explicitly associated with this
study (CT/C-MeSH) where nine descriptors (highlighted in bold) are in the ‘‘Disease” or ‘‘Chemicals and Drugs” MeSH hierarchies (A). Thirty-one descriptors are associated
with the study through PMIDs (CT/P-MeSH) where eight are in the required hierarchies (B). Links to over 236,000 sequences are identiﬁed where MeSH descriptors for 51 of
these sequences completely overlap (relevancy score = 100%) with respect to CT/C-MeSH (C).
12,277 2,209
330
36 163
37
622
Trials with unique PMID from
ClinicalTrials.gov
Trials with unique PMID from
PubMed/MEDLINE
Trials with common PMID from
ClinicalTrials.gov and PubMed/MEDLINE
Fig. 7. Source of PMIDs for clinical trials. The contribution of PMIDs from the
sources (ClinicalTrials.gov and PubMed/MEDLINE) is shown for clinical trials
examined in the present study. The upper-left circle represents the number of
trials with unique PMIDs contributed only by ClinicalTrials.gov; the upper-right
circle shows the number of trials with unique PMIDs contributed only by PubMed/
MEDLINE; the bottom circle depicts the number of trials with common PMIDs
contributed by both ClinicalTrials.gov and PubMed/MEDLINE.
E.S. Chen, I.N. Sarkar / Journal of Biomedical Informatics 43 (2010) 442–450 449an initial ﬁltering strategy (i.e., by ‘‘Diseases” and ‘‘Chemicals and
Drugs”). It is worth noting that in some cases a descriptor could
not be found (e.g., may be from an earlier version of MeSH) and
some descriptors fall into multiple hierarchies. Future work in-
cludes characterizing descriptors by semantic type or MeSH sub-
hierarchies and exploring additional ﬁltering strategies (e.g.,
including other hierarchies such as ‘‘Psychiatry and Psychology”).
The initial approach of using PMIDs and MeSH descriptors to
identifying potential relationships between sequences and trialsrevealed a vast number of linkages. Further evaluation of these
linkages will be valuable for assessing their relevance and guiding
the development of techniques for enhancing the ranking of
results.
5. Conclusion
The ability to integrate disparate publicly available biomedical
resources could be valuable for supporting and promoting research
across the bench-to-bedside (‘‘T1”) translational barrier. In this
study, we explored the feasibility of linking molecular sequences
in GenBank and clinical trials in ClinicalTrials.gov leveraging liter-
ature from PubMed/MEDLINE and keyword metadata in the form
of MeSH descriptors. The results obtained in this feasibility study
indicate that this is a promising approach for identifying relevant
linkages between sequences and trials.
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